Subscribe To

Price Alert Latest News Economic Calendar News

BIOC / Biocept reports 176% year-over-year jump in orders for CNSide assay

Biocept Inc (NASDAQ:BIOC) has reported a 176% year-over-year jump in orders for its CNSide product, a cerebrospinal fluid assay addressing unmet needs for patients with central nervous system metastasis. Commenting on its third-quarter results, Biocept CEO Samuel Riccitelli said the company was executing well on its strategy to generate further evidence to secure higher reimbursement for CNSide and support its adoption into clinical care guidelines. Read More

Demo Live Account See Partner Details

Content Topics

Biocept

Reports

176 Year

Over

Jump

Orders

Cnside

Assay

Year over year

Stock

BIOC

Posted: Nov 21 2022, 16:53

Author Name: Proactive Investors

BIOC News

By Seeking Alpha
August 30, 2023

Biocept, Inc. (BIOC) Business Update Conference Call (Transcript)

Biocept, Inc. (NASDAQ:BIOC ) Business Update Conference Call August 30, 2023 4:00 PM ET Company Participants Jody Cain - LHA Antonino Morales - Presid

By InvestorPlace
August 25, 2023

7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole

Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.

By Proactive Investors
August 14, 2023

Biocept CNSide assay takes the spotlight at 2023 SNO/ASCO CNS Cancer Conference

Biocept Inc (NASDAQ:BIOC) said that its CNSide cerebrospinal fluid assay was featured in two oral presentations at the 2023 Society for Neuro-Oncology

By Proactive Investors
June 21, 2023

Biocept appoints Antonino Morales as president and chief executive officer

Biocept Inc (NASDAQ:BIOC) has announced the appointment of Antonino Morales as its president and chief executive officer, effective immediately. Mora

By InvestorPlace
May 25, 2023

Why Is Biocept (BIOC) Stock Down 42% Today?

Biocept (NASDAQ: BIOC ) stock is falling hard on Thursday after the company revealed details of a public offering for its shares. Biocept is offering

By Proactive Investors
May 17, 2023

Biocept shares to commence trading on split-adjusted basis

Biocept has announced a one-for-thirty reverse stock split which became effective at 4:05pm Eastern Time on May 16, 2023. The company's common stock w

By Proactive Investors
April 17, 2023

Biocept outlines plans to get CNSide assay system commercially available, looks back on the 2022 financial year

Biocept Inc (NASDAQ:BIOC), which develops and commercializes molecular diagnostic assays, revealed new details about its plans to get its CNSide assay

By Proactive Investors
March 24, 2023

Biocept says enrollment begins in FORESEE clinical trial using CNSide to evaluate patients with leptomeningeal metastases

Biocept Inc (NASDAQ:BIOC), a provider of molecular diagnostic assays, products and services, revealed that the first patient with leptomeningeal metas

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.